TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7389390
Drug: Single night-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single night-time dose of chlordiazepoxide (5 mg) and amitriptyline (12.5 mg) - 3 capsules as a single dose at night
Study: 7389390
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily dosage regimen of chlordiazepoxide (5 mg) and amitriptyline (12.5 mg) - 1 capsule 3-times daily
Study: 25873137
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behavior therapy (iCBT)
Study: 21318572
Drug: Romiplostim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (1 μg/kg/week, escalated to 5 μg/kg/week, tapered over 12 weeks)
Study: 20532105
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg/kg mixed with ibuprofen 10 mg/kg (Group M)
Study: 20532105
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg/kg mixed with ibuprofen 10 mg/kg and ketamine 2 mg/kg (Group KM)
Study: 9201140
Drug: IVIG 250
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 250 mg/kg/day for 2 days
Study: 9201140
Drug: IVIG 400
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 400 mg/kg/day for 2 days
Study: 9201140
Drug: IVIG 500
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 500 mg/kg/day for 2 days
Study: 9201140
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg/day for 2 days (control)
Study: 24526895
Drug: Psychotherapeutic Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotherapeutic Intervention Module (PIM), n = 90, six therapy sessions over two months.
Study: 24526895
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU), n = 83.
Study: 20102918
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice 2,400 mg twice daily
Study: 676877
Drug: Gentamicin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1.0 mg/kg body-weight)
Study: 676877
Drug: Sisomicin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin (1.0 mg/kg body-weight)
Study: 676877
Drug: Amikacin (one-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (one-hour constant infusion)
Study: 676877
Drug: Tobramycin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1.0 mg/kg body-weight)
Study: 24909787
Drug: Intensive residential
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive residential treatment (IRT)
Study: 24909787
Drug: Intensive residential
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive residential treatment (IRT) responders
Study: 24909787
Drug: Intensive residential
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive residential treatment (IRT) participants who achieved wellness
Study: 9836546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pT1c and CIS
Study: 7926138
Drug: Veralipride 100
Normalized name: veralipride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride 100 mg/d
Study: 2913138
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with cat-dander extracts for 2 years (group A)
Study: 2913138
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with cat-dander extracts for 1 year (group B)
Study: 27388589
Drug: Liquid levothyroxine
Normalized name: levothyroxine Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid levothyroxine formulation
Study: 27388589
Drug: Tablet levothyroxine
Normalized name: levothyroxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet levothyroxine formulation
Study: 27388589
Drug: Levothyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine replacement therapy (both formulations)
Study: 25438937
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin D3 (6000 IU daily for 6 months)
Study: 22560018
Drug: Beta-blocker (BB)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (BB) dose
Study: 22560018
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of BB
Study: 17470957
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (40 sessions)
Study: 15182896
Drug: Network therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network therapy (NT)
Study: 12394686
Drug: Control (resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (resection alone or resection plus another treatment)
Study: 12394686
Drug: Intravesical bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical bacillus Calmette-Guerin (BCG) with maintenance treatment
Study: 8132849
Drug: Naproxen tablets
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets (250 mg)
Study: 8132849
Drug: Naproxen suspension
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen suspension (250 mg)
Study: 8132849
Drug: Naproxen tablets
Normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets and suspension
Study: 788749
Drug: Conventional oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional oxprenolol (80 mg)
Study: 30429032
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 (cohort A)
Study: 30429032
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 plus bevacizumab 15 mg/kg (cohort B)
Study: 30429032
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m2 (cohort C)
Study: 27440535
Drug: Conventional grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional grape juice (400 mL)
Study: 27440535
Drug: Organic grape
Normalized name: BENZALKONIUM CHLORIDE .13 TOPICAL LIQUID [Refresh Sanitizing Towlette Organic Grapefruit Splash]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic grape juice (400 mL)
Study: 24432999
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d sitagliptin with insulin therapy (group A)
Study: 24432999
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy without sitagliptin (group B)
Study: 18661005
Drug: Analgesic alone
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic alone
Study: 15955034
Drug: TM with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM with medication overuse (recent onset)
Study: 15955034
Drug: TM without
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TM without medication overuse (recent onset)
Study: 15955034
Drug: Recent onset
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent onset of chronic daily headache (CDH)
Study: 11773294
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT)
Study: 1279290
Drug: Doxazosin (1-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-16 mg) once daily for 16 weeks
Study: 3905414
Drug: BTS 49
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTS 49 465 (200 mg oral dose)
Study: 31060545
Drug: Visit frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit frequency determined by drug supply chain rather than clinical indication
Study: 26662208
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose rituximab (375 mg/m² weekly)
Study: 26662208
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rituximab (20 mg/m² 3x week)
Study: 26662208
Drug: Combination mAb
Normalized name: CCR5 mAb
DrugBank: CCR5 mAb (DB05906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination mAb therapy (alemtuzumab with either standard or low dose rituximab)
Study: 22400810
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant (ERN/LRPT) 1 gram/20 mg daily, increased to 2 tablets daily after 4 weeks
Study: 20170751
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly 1-hour sessions of CBT
Study: 1750635
Drug: Interpleural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpleural infusion of bupivacaine (Group B, n = 12)
Study: 1750635
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pethidine (Group P, n = 14)
Study: 1750635
Drug: Interpleural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpleural infusion of bupivacaine (Group B)
Study: 1750635
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pethidine (Group P)
Study: 30194380
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg per day for 1 week, then 50 mg per day up to 12 months)
Study: 25591756
Drug: Midazolam (MDZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MDZ) at a dose of 10 μmol/L in OGD+MDZ group
Study: 25591756
Drug: Midazolam (MDZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MDZ) at a dose of 10 μmol/L and IL‐6 at a dose of 50 ng/mL in OGD+MDZ+IL‐6 group
Study: 24307262
Drug: Na(18)F PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na(18)F PET/CT imaging at 45, 90, and 180 minutes after Na(18)F administration
Study: 22566743
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (CPAD‐IC)
Study: 19164456
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus gemcitabine (docetaxel 60 mg/m² on day 1 and day 8, gemcitabine 800 mg/m² on days 1 and 8, every 21 days)
Study: 19164456
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (docetaxel 60 mg/m² on day 1)
Study: 10577572
Drug: Candoxatril 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril 400 mg/day
Study: 6402051
Drug: 3.5% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% amino acid infusion
Study: 29218707
Drug: Rosuvastatin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin administered with food
Study: 29218707
Drug: Rosuvastatin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin administered in a fasting state
Study: 26765479
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing regimen (group A)
Study: 26765479
Drug: Pharmacokinetic model-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic model-based dosing scheme (group B)
Study: 23392267
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment model (intervention group)
Study: 23392267
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol (treatment-as-usual control group)
Study: 22337471
Drug: GRT9906 (120-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRT9906 (120-240 mg)
Study: 22337471
Drug: Tramadol (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200-400 mg)
Study: 15984517
Drug: WHF arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WHF arm (study group), 1000 mg/m2 of 5-FU administered over the course of 5 hr once a week by hepatic arterial infusion
Study: 15984517
Drug: CVI arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVI arm (control group), 300 mg/m2 of 5-FU administered as a continuous intravenous infusion daily for 5 days followed by 2 days' rest
Study: 9256127
Drug: Alternating schedule
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating schedule of chemotherapy and irradiation (CDE chemotherapy split into four courses of five daily fractions delivered on days 14 to 21 of the second and subsequent chemotherapy courses)
Study: 9256127
Drug: Sequential schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential schedule of chemotherapy and irradiation (five courses of CDE chemotherapy followed by thoracic irradiation 50 Gy in 20 daily fractions)
Study: 8289038
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (both treatment groups)
Study: 8289038
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment at home
Study: 3560788
Drug: Alinidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (3 X 40 mg for 2 weeks)
Study: 3560788
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 X 40 mg for 2 weeks)
Study: 30209286
Drug: Placebo 'analgesic'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 'analgesic' pills
Study: 12875474
Drug: Recommended exercise
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended exercise (oral and written instructions)
Study: 10375185
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation (leuploride and chlormadinone acetate) for 3 months preoperatively followed by radical prostatectomy and adjuvant endocrine therapy (leuploride only)
Study: 10375185
Drug: Radical prostatectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy followed by 3 months of androgen deprivation and subsequent adjuvant endocrine therapy
Study: 9038462
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 1 ml.kg‐1 of 0.25% bupivacaine with 0.25 mg.kg‐1 of preservative‐free ketamine
Study: 9038462
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1 ml.kg‐1 of 0.25% bupivacaine with 0.5 mg.kg‐1 of ketamine
Study: 9038462
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1 ml.kg‐1 of 0.25% bupivacaine with 1 mg.kg‐1 of ketamine
Study: 1442655
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg Ca as carbonate daily with meals)
Study: 3900116
Drug: Ritalin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin 0.3 mg/kg bid
Study: 3900116
Drug: Ritalin 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin 0.7 mg/kg bid
Study: 27129472
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (standardized weekly group yoga class with home practice)
Study: 25371053
Drug: anti-TNF (adalimumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-TNF (adalimumab, Humira®, Abbott) 40 mg s.c.
Study: 25371053
Drug: oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral methylprednisolone 20 mg/day during 7 days
Study: 22951084
Drug: Gabapentin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (maximum tolerable daily dose of 1800 mg)
Study: 19486025
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) 400 IU twice daily (D group)
Study: 17998780
Drug: Platelet-leukocyte gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-leukocyte gel (PLG)
Study: 16185403
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of L-arginine (2% of total caloric value)
Study: 16185403
Drug: Compound 14
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound 14 amino acid injection (2% of total caloric value)
Study: 12100090
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg butorphanol administered 1 min after sumatriptan
Study: 12100090
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg butorphanol administered 30 min after sumatriptan
Study: 12100090
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sumatriptan
Study: 12100090
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sumatriptan and butorphanol
Study: 10442961
Drug: Targeted injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted injections of 5 ml mepivacaine 1% with epinephrine (MEPE)
Study: 10442961
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 80 mL MEPE 1%
Study: 2191595
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg qid
Study: 25560820
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day of olive extract and 1000 mg Ca
Study: 25560820
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ca alone (placebo)
Study: 21336438
Drug: Conventional postoperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postoperative intravenous fluids (DNS group)
Study: 15702819
Drug: Fluticasone/salmeterol (250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol (250/50 microg twice daily)
Study: 22100357
Drug: Tropisetron (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (both doses)
Study: 18387159
Drug: Cinacalcet 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 12.5 mg
Study: 18387159
Drug: Cinacalcet 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 25 mg
Study: 18387159
Drug: Cinacalcet 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 50 mg
Study: 6145734
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam with a narcotic
Study: 28954218
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (Detemir, Aspart, and their combination) as an add-on to metformin for 4 weeks
Study: 24602411
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (up to 16 mg/24 h)
Study: 16415516
Drug: Bicarbonated Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonated Ringer's solution
Study: 8734709
Drug: Neither medication
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither medication group
Study: 2021446
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic (n = 1,625)
Study: 30452739
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch and behavioral counseling
Study: 30153360
Drug: Active bifrontal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active bifrontal tDCS with concurrent CBT
Study: 30153360
Drug: Sham bifrontal
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham bifrontal tDCS with concurrent CBT
Study: 21106282
Drug: liposomal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal placebo gel
Study: 19843060
Drug: Clozapine-Risperidone (CLZ-RISP)
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine-Risperidone (CLZ-RISP) combination
Study: 2496989
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection of 0.1, 0.25 or 0.5 ml of diphtheria-tetanus vaccine
Study: 197502
Drug: Nursing services
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing services (treatment group)
Study: 23642981
Drug: Brief psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic therapy (24 subjects)
Study: 23642981
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (25 subjects)
Study: 3111179
Drug: Novel aldose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel aldose reductase inhibitor (ARI)
Study: 3111179
Drug: ARI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARI treatment
Study: 31531997
Drug: Immunonutrition supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition supplements (3 supplements/day for 5 days)